TC
Truffle Capital
Private EquityActiveTruffle Capital is an independent European private equity firm originally set up for investing in technology spin-offs.
38
Investments
9
Exits
$1.2B
AUM
23.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Truffle Capital.
Investment Thesis & Strategy
Truffle Capital invests in various stages of fintech and technology spin-off companies, leveraging its European private equity background. They seek to invest in innovative companies with high growth potential.
Investment Activity
Deals per year over the last 12 years
2
20100
20113
20122
20132
20140
20150
20160
20171
20181
20190
20201
2021Portfolio Companies
Selected investments from their portfolio of 38 companies
T
Truffle Therapeutics
Biotech · Growth, 2021
A
Atawey
Cleantech · Growth, 2019
A
Abionyx Pharma
Biotech · Growth, 2018
H
Horama
Biotech · Growth, 2014
I
Inventiva
Biotech · Growth, 2014
P
Pixium Vision
Biotech · Growth, 2013
B
Biom'up
Healthcare · Growth, 2013
N
Novacyt
Biotech · Growth, 2012
D
DBV Technologies
Biotech · Growth, 2012
N
Nanobiotix
Biotech · Growth, 2012
V
Vexim
Healthcare · Growth, 2010
E
Ekinops
Enterprise · Growth, 2010
Notable Exits
CompanyTypeYearValue / Acquirer
MaaT PharmaIPO2021—
AbivaxIPO2018—
InventivaIPO2017—
OSE ImmunotherapeuticsIPO2016—
DBV TechnologiesIPO2014$360M
Pixium VisionIPO2014—
NanobiotixIPO2012—
VeximIPO2012—
CarmatIPO2010—
Frequently Asked Questions
Truffle Capital focuses on Series B, Series C+ stage investments.